Azitra, Inc.

AMEX:AZTR

Biotechnology

Healthcare
$1.53 +113.99%

+$0.82 today

Market cap
$92.72M
Beta
-1.04
P/E (TTM)
-1.2
EPS (TTM)
-$0.64
52W Low $0.05High $2.13

Volume 146.25M

Average 11.12M

AZTR Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Azitra, Inc.AMEX: AZTR

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) growth accelerates

Q2 FY2026 weighted avg shares (diluted) of 19.3M shares rose 689.6% year over year, ahead of the +671.4% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 24.4% from the prior quarter. Over 3 fiscal years it compounded at +331.9% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +689.6% holds above the trailing-twelve-month pace of +671.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
19.3M+24.4% QoQ
Last fiscal yearDec 2025
4.87M+757.7% YoY
LTMJun 2026
12.42M+671.4% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+689.6%——
1 year+757.7%——
3-year CAGR+331.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
4.87M USD
Year-over-year change
+757.7%
4-year CAGR
+199.6%

Weighted Avg Shares (Diluted) vs competitors

How AZTR compares with its peers on the latest reported figures

  • AZTR's LTM Jun 2026 weighted avg shares (diluted) of 12.42M shares is the highest of the 2 companies compared; the peer median is 3.96M shares.
  • Its year-over-year change of +671.4% is the highest of 2, against a peer median of -56.9%.
  • Over three fiscal years its annual growth of +331.9% compares with a peer median of -51.1%.
AZTR Competitors Peer median
Weighted Avg Shares (Diluted) for AZTR and competitors
Company Period LTM YoY 3-year CAGR
AZTRAzitra, Inc.LTM Jun 202612.42M +671.4%+331.9%
INDPIndaptus Therapeutics, Inc.LTM Mar 20263.96M -56.9%-51.1%
Peer median (excluding AZTR) 3.96M-56.9%-51.1%

Competitors are the stored peer set for AZTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue110K284K686K7.5K0
Cost of Revenue00000
Gross Profit110K284K686K7.5K0
Gross Margin100.0%100.0%100.0%100.0%—
Research & Development5.38M6.1M3.64M4.72M4.84M
Selling, General & Admin3.95M3.64M4.49M6.27M6.13M
Operating Expenses9.33M9.74M8.14M10.99M10.97M
Depreciation & Amortization84.77K405.98K425.55K448.24K453.14K
EBITDA(8.79M)(10.02M)(10.67M)(8.5M)(10.49M)
EBITDA Margin-7989.0%-3529.0%-1555.9%-113307.5%—
Operating Income(9.22M)(9.45M)(7.45M)(10.99M)(10.97M)
Operating Margin-8383.1%-3328.7%-1086.1%-146468.5%—
Interest Income8.76K4.82K1.58K122.55K70.21K
Interest Expense66.97K251.89K167.73K12.16K7.59K
Other Income / Expenses281.78K(1.23M)(3.82M)2.03M19.61K
Income Before Tax(8.94M)(10.68M)(11.27M)(8.96M)(10.95M)
Pre-Tax Margin-8127.0%-3760.7%-1642.3%-119446.1%—
Income Tax Expense0017.31K9.03K8.32K
Net Income(8.94M)(10.68M)(11.28M)(8.97M)(10.96M)
Net Margin-8127.0%-3760.7%-1644.9%-119566.6%—
EPS (Basic)(193.55)(222.33)(208.74)(15.78)(2.25)
EPS (Diluted)(193.55)(222.33)(208.74)(15.78)(2.25)
Weighted Avg Shares60.49K60.49K60.55K568.24K4.87M
Weighted Avg Shares (Diluted)60.49K60.49K60.55K568.24K4.87M

Azitra, Inc.

AMEX:AZTR

Intrinsic Alpha fair value

Locked

Current Price

$1.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.